Expression of lncRNA-p21 in lung adenocarcinoma tissue and its relationship with pathological parameters and prognosis

doi:10.3877/cma.j.issn.1674-0785.2021.09.006

Abstract

Abstract:

Objective

To investigate the relationship between long non-coding ribonucleic acid (lncRNA)-p21 expression and clinicopathological parameters and prognosis in lung adenocarcinoma.

Methods

A total of 96 patients with lung adenocarcinoma admitted to the Affiliated Hospital of Xuzhou Medical University from January 2015 to December 2017 were selected, and the surgically resected cancer tissues and paracancerous tissues (more than 5 cm away from the edge of cancer tissues) were taken to detect the expression of lncRNA-p21 by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR). The relationship between lncRNA-p21 expression and clinicopathological parameters was analyzed. After 3 years of postoperative follow-up, Kaplan-Meier survival curves were plotted for lung adenocarcinoma patients with different lncRNA-p21 expression, and the prognostic factors of lung adenocarcinoma patients were analyzed with the Cox proportional risk model.

Results

The relative expression of lncRNA-p21 in lung adenocarcinoma tissues was lower than that in adjacent tissues (1.03±0.27 vs 3.02±0.81, P＜0.05). The relative expression of lncRNA-p21 in patients with tumor diameter ≥3 cm, low to moderate tumor differentiation, T₃ stage, and N₂ stage were lower than those in patients with tumor diameter＜3 cm, high tumor differentiation, T_1-2 stage, and N_0-1 stage, respectively (P＜0.05 for all). The 3-year overall survival (OS) rate and progression free survival (PFS) rate of patients with low expression of lncRNA-p21 were lower than those with high expression of lncRNA-p21 (38.78% vs 63.83%, 8.16% vs 34.04%, P＜0.05 for both). Cox proportional risk regression analysis showed that N stage [hazard ratio (HR)=1.881, 95% confidence interval (CI): 1.340-2.641, P＜0.001] and low expression of lncRNA-p21 (HR=0.609, 95%CI: 0.453-0.819, P=0.001) were associated with a poor prognosis in patients with lung adenocarcinoma.

Conclusion

The expression of lncRNA-p21 is down-regulated in lung adenocarcinoma tissue, and the low expression of lncRNA-p21 is associated with tumor size, differentiation degree, TN stage and poor prognosis.

Key words: Lung adenocarcinoma, Long non-coding ribonucleic acid, Clinicopathological parameters, Prognosis

Yue Jin, Teng Sun, Yanliang Yuan, Hao Zhang. Expression of lncRNA-p21 in lung adenocarcinoma tissue and its relationship with pathological parameters and prognosis[J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(09): 672-677.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2021.09.006

https://zhlcyszz.cma-cmc.com.cn/EN/Y2021/V15/I09/672

Figures/Tables 4

References 24

1	石少敏, 赵建军, 于杜鹃, 等. miR-320a靶向Rab11a调控非小细胞肺癌细胞增殖的研究 [J]. 中国实验诊断学, 2018, 22(9): 1636-1638.
2	Sanchez Calle A, Kawamura Y, Yamamoto Y, et al. Emerging roles of long non-coding RNA in cancer [J]. Cancer Sci, 2018, 109(7): 2093-2100.
3	Zhou W, Chen X, Hu Q, et al. Galectin-3 activates TLR4/NF-κB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression [J]. BMC Cancer, 2018, 18(1): 580.
4	Liu L, Liu L, Lu S. lncRNA H19 promotes viability and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-29b-3p and modifying STAT3 [J]. Int J Oncol, 2019, 54(3): 929-941.
5	Luo J, Wang K, Yeh S, et al. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling [J]. Nat Commun, 2019, 10(1): 2571.
6	Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention [J]. Clin Chest Med, 2011, 32(4): 605-644.
7	Ghafouri-Fard S, Shirvani-Farsani Z, Hussen BM, et al. The critical roles of lncRNAs in the development of osteosarcoma [J]. Biomed Pharmacother, 2021, 135: 111217.
8	Tang Q, Hann SS. HOTAIR: An oncogenic long non-coding RNA in human cancer [J]. Cell Physiol Biochem, 2018, 47(3): 893-913.
9	Collette J, Le Bourhis X, Adriaenssens E. Regulation of human breast cancer by the long non-coding RNA H19 [J]. Int J Mol Sci, 2017, 18(11): 2319.
10	Jia Y, Duan Y, Liu T, et al. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5 [J]. Cell Death Dis, 2019, 10(8): 573.
11	Zhao M, Xin XF, Zhang JY, et al. LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling [J]. Cancer Med, 2020, 9(3): 1196-1208.
12	Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development [J]. Nat Rev Genet, 2014,15(1): 7-21.
13	Yang F, Zhang H, Mei Y, et al. Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the Warburg effect [J]. Mol Cell, 2014, 53(1): 88-100.
14	Dimitrova N, Zamudio JR, Jong RM, et al. LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint [J]. Mol Cell, 2014, 54(5): 777-790.
15	Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response [J]. Cell, 2010, 142(3): 409-419.
16	Wang X, Ruan Y, Wang X, et al. Long intragenic non-coding RNA lincRNA-p21 suppresses development of human prostate cancer [J]. Cell Prolif, 2017, 50(2): e12318.
17	Işın M, Uysaler E, Özgür E, et al. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease [J]. Front Genet, 2015, 6: 168.
18	Yan MD, Lin HY, Hwang PA. The anti-tumor activity of brown seaweed oligo-fucoidan via lncRNA expression modulation in HepG2 cells [J]. Cytotechnology, 2019, 71(1): 363-374.
19	裴洪利, 白尚星. 过表达lncRNA-p21通过介导Wnt/β-catenin信号通路抑制胃癌MGC-803细胞的生长与转移 [J]. 临床与病理杂志, 2019, 39(8): 1615-1621.
20	Ding J, Xie M, Lian Y, et al. Long noncoding RNA HOXA-AS2 represses P21 and KLF2 expression transcription by binding with EZH2, LSD1 in colorectal cancer [J]. Oncogenesis, 2017, 6(1): e288.
21	汪小霞, 孟刚, 李丽, 等. 乳腺癌中EZH2和p53蛋白表达及其临床意义 [J]. 临床与实验病理学杂志, 2015, 31(3): 273-276.
22	Jiang B, Chen J, Yuan W, et al. Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating notch1 and matrix metalloproteinase 9 [J]. Oncol Lett, 2018, 15(2): 1573-1579.
23	张冠磊, 马苗苗, 兰文静, 等. LncRNA-p21调控Notch信号通路对非小细胞肺癌A549细胞增殖、迁移及侵袭的影响 [J]. 肿瘤防治研究, 2021, 48(2): 121-126.
24	张卫强, 赵京, 刘克强, 等. miR-25-3p和PHLPP2在肺腺癌中的表达及其与预后的相关性分析 [J]. 重庆医学, 2020, 49(23): 3936-3940.

项目	例数	LncRNA-p21表达
年龄
＜60岁	51	1.05±0.19
≥60岁	45	1.02±0.23
t值		0.699
P值		0.486
性别
男	58	0.99±0.26
女	38	1.09±0.21
t值		1.984
P值		0.050
吸烟史
有	61	1.01±0.25
无	35	1.06±0.22
t值		0.984
P值		0.328
肿瘤直径
≥ 3 cm	51	0.93±0.09
＜3 cm	45	1.14±0.05
t值		13.872
P值		＜0.001
分化程度
低中度分化	65	0.96±0.11
高度分化	31	1.18±0.10
t值		9.428
P值		＜0.001
T分期
T_1~2期	63	1.11±0.04
T₃期	33	0.88±0.05
t值		24.514
P值		＜0.001
N分期
N_0~1期	80	1.07±0.04
N₂期	16	0.83±0.02
t值		23.351
P值		＜0.001

项目	例数	LncRNA-p21表达
年龄
＜60岁	51	1.05±0.19
≥60岁	45	1.02±0.23
t值		0.699
P值		0.486
性别
男	58	0.99±0.26
女	38	1.09±0.21
t值		1.984
P值		0.050
吸烟史
有	61	1.01±0.25
无	35	1.06±0.22
t值		0.984
P值		0.328
肿瘤直径
≥ 3 cm	51	0.93±0.09
＜3 cm	45	1.14±0.05
t值		13.872
P值		＜0.001
分化程度
低中度分化	65	0.96±0.11
高度分化	31	1.18±0.10
t值		9.428
P值		＜0.001
T分期
T_1~2期	63	1.11±0.04
T₃期	33	0.88±0.05
t值		24.514
P值		＜0.001
N分期
N_0~1期	80	1.07±0.04
N₂期	16	0.83±0.02
t值		23.351
P值		＜0.001

因素	β	SE	Wald χ²值	HR值	95%CI	P值
年龄	-0.202	0.154	1.721	0.817	0.604~1.105	0.692
性别	0.125	0.103	1.473	1.133	0.926~1.387	0.721
吸烟史	0.207	0.179	1.337	1.230	0.866~1.747	0.809
肿瘤直径	0.275	0.197	1.949	1.317	0.895~1.937	0.407
分化程度	0.465	0.156	6.824	1.592	1.173~2.161	0.020
T分期	0.531	0.173	7.415	1.700	1.212~2.387	0.015
N分期	0.703	0.212	10.996	2.020	1.333~3.060	＜0.001
LncRNA-p21	-0.532	0.181	8.639	0.587	0.412~0.838	0.006

因素	β	SE	Wald χ²值	HR值	95%CI	P值
年龄	-0.202	0.154	1.721	0.817	0.604~1.105	0.692
性别	0.125	0.103	1.473	1.133	0.926~1.387	0.721
吸烟史	0.207	0.179	1.337	1.230	0.866~1.747	0.809
肿瘤直径	0.275	0.197	1.949	1.317	0.895~1.937	0.407
分化程度	0.465	0.156	6.824	1.592	1.173~2.161	0.020
T分期	0.531	0.173	7.415	1.700	1.212~2.387	0.015
N分期	0.703	0.212	10.996	2.020	1.333~3.060	＜0.001
LncRNA-p21	-0.532	0.181	8.639	0.587	0.412~0.838	0.006

因素	β	SE	Wald χ²值	HR值	95%CI	P值
分化程度	0.302	0.261	1.339	1.353	0.811~2.256	0.705
T分期	0.365	0.297	1.510	1.441	0.805~2.578	0.621
N分期	0.632	0.173	13.346	1.881	1.340~2.641	＜0.001
LncRNA-p21	-0.496	0.151	10.790	0.609	0.453~0.819	0.001

Please choose a citation manager

Content to export